NEWARK, Del., Nov. 7, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced that it has set November 3, 2011 as the Record Date for its 2011 Annual Stockholders Meeting to be held December 8, 2011 at iBio’s facilities located at 9 Innovation Way, Newark, Delaware commencing at 11:00 AM ET.
Although only stockholders of record as of the close of business on November 3, 2011 will be entitled to vote at the meeting, anyone with proof of ownership of iBio shares will be welcome to attend. Others may be invited to attend by contacting Douglas Hicks, iBio’s Vice President, Business Development, at 302-355-2313.
Senior management will be present to review business developments, including new patents granted and progress on new product applications of our iBioLaunch technology, since the prior Annual Meeting. Subject to preemption by possible production activities required to be accomplished that day, a limited number of pre-registered attendees may have an opportunity to tour the laboratories and the GMP pilot plant. For information and pre-registration, please contact Douglas Hicks.
About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com.
Forward-Looking Statements
Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as lack of available capital, intellectual property protection issues, competitive factors, technological development, market demand, and the Company’s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company’s financial results can be found in the company’s Reports filed with the Securities and Exchange Commission.
Contacts: | ||
Corporate: | Investor Contacts: | |
Robert Erwin, President | Douglas Beck, CFO | |
iBio, Inc. | iBio, Inc. | |
302-355-2335 | 302-355-0923 | |
SOURCE iBio, Inc.
